~~Table~~UNITED STATES SECURITIES ofAND ~~Contents~~EXCHANGE COMMISSION

~~UNITED STATES~~WASHINGTON, ~~SECURITIES~~D.C. ~~AND EXCHANGE COMMISSION~~ 20549

~~Washington, D.C. 20549~~ FORM 8-K

~~FORM~~CURRENT ~~8-K~~REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

~~CURRENT~~DATE ~~REPORT~~OF ~~Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934~~ REPORT

~~Date of Report~~ (~~Date~~DATE ofOF EARLIEST ~~earliest~~EVENT ~~event reported~~REPORTED): ~~May 17, 2009~~

~~IDM PHARMA~~June 23, ~~INC.~~ 2009

~~(Exact~~IDM PHARMA, ~~Name of Registrant as Specified in Charter)~~INC.

Delaware	0-19591	33-0245076
(State or Other Jurisdiction	(Commission	(IRS Employer
of Incorporation)	File Number)	Identification No.)

(Exact Name of Registrant as Specified in Charter)

9 Parker, Suite 100 Irvine, California (Address of principal executive offices) 92618 (Zip Code)

Delaware		0-19591		33-0245076
(State or Other Jurisdiction of Incorporation or Organization)		(Commission File Number)		(IRS Employer Identification No.)

~~Registrant’s~~9 Parker, ~~telephone number~~Suite 100 Irvine, ~~including~~California ~~area code (949) 470-4751~~92618

(~~Former Name or Former~~ Address, ifof ~~Changed~~Principal Executive ~~Since~~Offices) (Zip ~~Last Report.~~Code)

~~Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions~~ (~~see General Instruction A.2. below~~949): 470-4751

~~o Written communications pursuant to Rule 425 under the Securities Act~~ (17Registrant’s ~~CFR~~telephone number, ~~230.425)~~including oarea ~~Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12~~code) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~TABLE~~(Former OFName ~~CONTENTS~~or Former Address, if Changed Since Last Report)

~~Item~~Check ~~1.01.~~the ~~Entry~~appropriate ~~into~~box abelow if ~~Material~~the ~~Definitive~~Form 8-K ~~Agreement~~filing ~~Item~~is ~~5.02.~~intended ~~Departure~~to ofsimultaneously ~~Directors~~satisfy orthe ~~Certain~~filing obligation ~~Officers; Election~~ of ~~Directors;~~the ~~Appointment~~registrant ofunder ~~Certain~~any ~~Officers; Compensatory Arrangements~~ of ~~Certain~~the ~~Officers~~following ~~Item~~provisions ~~9.01.~~(see ~~Financial~~General Instruction ~~Statements and Exhibits SIGNATURES INDEX TO EXHIBITS EX-~~A.2.1 ~~EX-10.1 EX-99.1~~below):

~~Table~~o Written communications ofpursuant ~~Contents~~to Rule 425 under the Securities Act (17 CFR 230.425)

~~Item~~o Soliciting material pursuant to Rule ~~1.01.~~14a-12 ~~Entry~~under ~~into~~the aExchange ~~Material~~Act ~~Definitive~~(17 ~~Agreement.~~CFR 240.14a-12)

Ono Pre-commencement communications ~~May 18,~~pursuant ~~2009,~~to ~~IDM Pharma, Inc.~~ Rule 14d-2(~~“IDM”~~b), under ~~entered~~the ~~into~~Exchange anAct ~~Agreement and Plan of Merger~~ (~~the~~17 ~~“Merger~~CFR ~~Agreement”) with Takeda America Holdings, Inc~~240.~~, a New York corporation~~ 14d-2(~~“Takeda America”~~b) ~~and Jade Subsidiary Corporation, a Delaware corporation and wholly owned subsidiary of Takeda America (“Purchaser”~~), pursuant to which, among other things, Purchaser has agreed to commence a tender offer for all the outstanding shares of common stock of IDM, subject to the terms and conditions contained in the Merger Agreement.

Ono Pre-commencement ~~May 18,~~communications ~~2009,~~pursuant ~~Takeda~~to ~~Pharmaceutical Company Limited, a corporation organized~~ Rule 13e-4(c) under ~~the laws of~~ ~~Japan and~~ the ~~parent~~Exchange ofAct ~~Takeda America~~ (~~“TPC”)~~17 ~~and~~CFR ~~IDM issued a joint press release relating to the Merger Agreement~~240. ~~A copy of the press release was previously furnished by IDM on a Schedule 14D~~13e-~~9C, filed with the Securities and Exchange Commission~~ 4(~~“SEC”~~c) ~~on May 18, 2009.~~ )

~~Merger~~Item ~~Agreement~~ 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

~~Pursuant~~On toJune 23, ~~the~~2009, Takeda ~~Merger~~America ~~Agreement~~Holdings, Inc. ~~and upon~~ (the ~~terms~~“Parent”), ~~and~~a ~~subject~~wholly toowned ~~the~~subsidiary ~~conditions contained~~of ~~therein,~~Takeda ~~Purchaser~~Pharmaceutical isCompany ~~obligated~~Limited ~~to commence a tender offer~~ (~~the~~ “~~Offer~~TPC”), tocompleted ~~acquire~~its acquisition of all of the outstanding shares of ~~IDM~~ common stock, par value $0.01 per share, of IDM Pharma, Inc. (the “~~Shares~~Company”), ~~for~~pursuant $2to an Agreement and Plan of Merger (the “Merger Agreement”), dated as of May 18, 2009, among the Parent, the Company and Jade Subsidiary Corporation (the “Merger Sub”), a wholly owned subsidiary of the Parent.64 The ~~per~~Parent’s acquisition ~~Share~~of the capital stock of the Company was structured as a two-step transaction, ~~net~~with toa tender offer made through the Merger Sub for all of the outstanding shares of the ~~seller~~Company incommon ~~cash~~stock (the “Offer”) ~~Price~~followed by a merger of the Merger Sub with and into the Company (the “Merger”)., with the Company becoming the surviving corporation and a wholly owned subsidiary of the Parent.

The ~~Merger~~initial ~~Agreement~~offering ~~provides~~period of ~~that Purchaser will commence~~ the Offer asexpired ~~promptly~~at as12:00 ~~reasonably practicable~~midnight, ~~(but~~New noYork ~~later~~City ~~than~~time, ~~seven~~at ~~business days) after~~ the ~~initial~~end ~~public announcement~~ of ~~the~~ ~~execution~~Monday, ofJune 22, ~~the Merger Agreement~~2009. According ~~The~~to American ~~initial~~Stock ~~expiration~~Transfer & ~~date~~Trust ofCompany, the ~~Offer~~depositary ~~is 20 business days following the commencement~~ of the Offer, ~~and the Offer may be extended under certain circumstances~~ ~~described~~as inof the ~~Merger~~expiration ~~Agreement.~~of ~~Under no circumstances may~~ the ~~Offer~~initial beoffering ~~extended beyond July 22~~period, ~~2009.~~a ~~Purchaser’s~~total ~~obligation~~of ~~to accept for payment and pay for Shares tendered in the Offer is~~approximately ~~subject to certain conditions~~21, ~~including~~842,929 ~~among~~shares ~~other things, that at least a majority~~ of the ~~outstanding~~ ~~Shares~~Company oncommon astock ~~fully diluted basis~~ (~~which~~including ~~includes~~shares ~~Shares~~tendered ~~that are issuable pursuant to~~under ~~outstanding~~guaranteed ~~IDM~~delivery ~~warrants and options~~procedures) ~~shall~~had ~~have~~ been validly tendered (pursuant to the Offer and not properly withdrawn~~) in~~, ~~accordance~~representing ~~with~~approximately ~~the~~86.4% ~~terms~~ of the ~~Offer (the “Minimum Condition”). Pursuant to the Merger~~outstanding ~~Agreement,~~shares ~~as soon as practicable after Purchaser’s acceptance~~ of ~~Shares tendered in~~ the ~~Offer,~~Company. On ~~and~~June 23, ~~subject~~2009, to the ~~satisfaction or waiver of certain conditions set forth in the~~ Merger ~~Agreement, Purchaser~~Sub isaccepted ~~obligated~~for topurchase ~~acquire~~ all ofshares ~~the Shares~~ that were ~~not~~ validly tendered, ~~through~~and anot ~~merger~~properly ofwithdrawn. ~~Purchaser~~Stockholders ~~with~~who ~~and~~validly ~~into~~tendered ~~IDM with IDM being the surviving corporation~~ and adid ~~wholly~~not ~~owned~~properly ~~subsidiary~~withdraw their ofshares ~~Takeda~~will ~~America~~promptly ~~(the~~receive ~~“Merger”)~~$2.64 Atper ~~the~~share, ~~effective~~net ~~time~~to of the ~~Merger,~~seller ~~each~~in ~~issued~~cash ~~and outstanding Share~~ (~~other~~the ~~than~~“Offer ~~Shares~~Price”). The ~~held~~Offer byPrice ~~stockholders~~paid ~~who~~or ~~have~~payable ~~perfected~~for ~~their~~shares ~~statutory~~tendered ~~rights~~in ~~of appraisal under Section 262 of~~ the ~~Delaware~~Offer ~~General~~is ~~Corporation~~subject ~~Law)~~to any ~~will~~applicable betax ~~automatically~~withholding, ~~canceled~~ and ~~converted~~no ~~into~~interest ~~the~~will ~~right~~be topaid ~~receive the Offer Price~~thereon.

~~The~~A ~~Merger~~copy ~~Agreement~~of ~~grants Purchaser an option (~~the ~~“Top-Up~~press ~~Option”) to acquire directly from IDM~~release ~~a number of newly-~~issued ~~Shares~~by ~~equal~~TPC toannouncing the ~~lesser~~completion of ~~(i)~~ the ~~number~~Offer ofis ~~Shares~~filed ~~that, when added to the number of Shares owned by Purchaser~~ as of immediately prior to the exercise of the Top-Up Option , constitutes one share more than 90% of the number of Shares that would be outstanding immediately after the issuance of all Shares subject to the Top-Up Option or (ii)Exhibit ~~the aggregate~~99.1 ~~number of Shares that IDM is authorized~~ to ~~issue~~this ~~under~~Current ~~its~~Report ~~Amended~~on ~~and Restated Certificate of Incorporation, as amended, but that are not issued and outstanding or otherwise committed to be issued at the time of exercise of the Top~~Form 8-~~Up Option~~K.

~~The~~On ~~Merger~~June 24, ~~Agreement~~2009, pursuant ~~includes~~to ~~customary~~the ~~representations,~~terms ~~warranties~~ and ~~covenants~~conditions of ~~IDM,~~the ~~Takeda America~~Merger ~~and Purchaser~~Agreement, ~~including~~the ~~certain~~Merger ~~operating~~Sub was ~~covenants~~merged ~~related~~with toand ~~IDM’s~~into ~~business.~~the ~~IDM~~Company ~~has also~~and ~~agreed~~each ~~not~~remaining tooutstanding ~~solicit,~~share ~~initiate,~~of the ~~knowingly~~Company ~~encourage~~common orstock ~~knowingly~~(other ~~facilitate~~than (1) any ~~third~~shares ~~party acquisition~~held ~~proposals~~by ~~for~~the ~~IDM.~~Company ~~The~~as treasury ~~Merger~~stock ~~Agreement~~or ~~also~~owned ~~includes~~by ~~termination~~the ~~provisions~~Parent, ~~for~~the ~~both IDM~~Merger ~~and~~Sub ~~Takeda~~or ~~America~~any ~~and~~subsidiary ~~provides~~of ~~that~~the Company, ~~in connection with~~ the ~~termination~~Parent ofor the Merger ~~Agreement~~ ~~under~~Sub ~~specified~~and ~~circumstances,~~(2) any ~~IDM~~shares ~~will~~held beby ~~required~~a toholder who ~~pay~~did tonot ~~Takeda~~vote ~~America~~in ~~a termination~~favor ~~fee~~ of ~~$2.25 million,~~or ~~subject~~consent to ~~offset~~the byMerger ~~any~~and ~~expense~~who ~~reimbursement~~properly ~~amounts previously~~demands ~~paid~~and byperfects ~~IDM.~~his, ~~IDM~~her ~~will~~or beits ~~obligated~~right to ~~reimburse~~be ~~Takeda~~paid ~~America’s~~the ~~actual~~fair ~~expenses~~value of upsuch toshares ~~$750,000~~ in accordance ~~connection~~ with Delaware law) was automatically cancelled and converted into the ~~termination~~right ofto receive the ~~Merger~~same ~~Agreement~~consideration ~~under~~per ~~specified~~share ~~circumstances~~paid in the Offer.

~~The~~A ~~closing~~copy of the ~~Merger~~press isrelease issued ~~subject~~by tothe ~~customary~~TPC ~~closing~~announcing ~~conditions. Depending on~~ the ~~number~~completion of ~~Shares~~ ~~held by Purchaser after Purchaser’s acceptance of~~ the ~~Shares~~acquisition ~~tendered~~is infiled ~~accordance~~as ~~with the~~Exhibit 99.2 ~~terms~~to ofthis ~~the~~Current ~~Offer~~Report ~~(and,~~on if Form 8-K.

~~Table~~The foregoing description of ~~Contents~~the Merger Agreement is qualified in its entirety by reference to the Merger Agreement, a copy of which was filed as Exhibit 2.1 to the Form 8-K filed by the Company on May 18, 2009.

~~applicable,~~As ~~Purchaser’s~~a ~~acquisition~~result of ~~Shares pursuant to~~ the ~~Top-Up Option)~~Merger, the ~~approval~~Company ofno ~~the~~longer ~~Merger~~fulfills by the ~~holders~~numerical oflisting ~~the~~requirements ~~outstanding~~of ~~Shares~~The ~~after~~Nasdaq Global ~~the~~Market ~~completion of~~(“Nasdaq”). Accordingly, ~~the~~on ~~Offer~~June 24, ~~may~~2009, beat ~~required.~~ the

~~A copy of the Merger Agreement is attached as Exhibit~~ 2.1 to this report and is incorporated herein by reference. The foregoing description of the Merger Agreement does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement.

~~The~~Company’s ~~Merger~~request, ~~Agreement~~The ~~has~~NASDAQ ~~been~~Stock ~~included~~Market toLLC ~~provide investors and stockholders~~ filed with ~~information regarding~~the ~~its terms~~U. ~~It is not intended to provide any other factual information about IDM~~S. ~~The Merger~~Securities ~~Agreement contains representations~~ and ~~warranties~~Exchange ~~that~~Commission ~~the parties to the Merger Agreement made to~~ (~~and solely for~~ the ~~benefit of~~“SEC”) ~~each~~a ~~other.~~Notification ~~The assertions embodied in the representations and warranties~~ of ~~IDM are qualified by information contained in the confidential disclosure~~ ~~schedules~~Removal ~~that~~from ~~IDM~~Listing ~~delivered~~and/or inRegistration ~~connection~~under ~~with~~Section 12(b) of ~~signing~~ the ~~Merger Agreement as well as by~~ ~~information~~Securities ~~contained~~Exchange ~~the~~Act ~~Annual~~of ~~Report on Form 10-K for the fiscal year ended December 31~~1934, ~~2008,~~ as amended by (the ~~Annual~~“Exchange ~~Report~~Act”), on Form 25 to ~~10-K/A~~effect ~~and~~ the ~~Quarterly~~delisting ~~Report~~of onshares ~~Form~~of ~~10-Q~~Company ~~for~~common ~~the quarter~~stock ~~ended~~from ~~March 31,~~Nasdaq ~~2008 (the “SEC Reports”). Accordingly, investors~~ and ~~stockholders should~~the ~~not~~deregistration ~~rely on such representations and warranties as characterizations~~ of the ~~actual~~Company ~~state~~common ofstock ~~facts or~~under ~~circumstances~~the ~~described~~Exchange ~~therein~~Act. In ~~Moreover~~addition, ~~information concerning~~ the ~~subject~~Company ~~matter~~will offile ~~such~~with the ~~representations~~SEC ~~and~~a ~~warranties~~Certification ~~may~~on ~~change~~Form 15 ~~after~~under the ~~date~~Exchange ofAct ~~the~~to ~~Merger~~suspend ~~Agreement, which subsequent~~the ~~information~~Company’s ~~may~~reporting orobligations ~~may~~under ~~not~~Sections be13(a) and ~~fully~~15(d) of ~~reflected in~~ the Exchange ~~parties’ public disclosures~~Act.

~~Stockholders’~~Item ~~Agreement~~3.02 Unregistered Sales of Equity Securities

InPursuant connection with the Offer, Takeda America and certain of IDM’s stockholders (the “Signing Stockholders”) have entered into a Stockholders’ Agreement, dated as of May 18, 2009 (the “Stockholders’ Agreement”). As of May 18, 2009, the outstanding Shares subject to ~~the Stockholders’~~ ~~Agreement represent approximately 55% of~~ the ~~total~~top-up ~~outstanding~~option ~~Shares~~granted ~~and approximately 49% of Shares outstanding on a fully diluted basis for purposes of determining the Minimum Condition. Pursuant~~ to the ~~Stockholders’~~Merger ~~Agreement,~~Sub ~~each of the Signing Stockholders agreed,~~ in ~~their capacities as stockholders of IDM, among other things, (i) subject to~~ the ~~termination~~Merger ~~of the Stockholders’~~ Agreement, toon ~~tender or cause to be tendered in the Offer all Shares beneficially owned or subsequently acquired by them, (ii)~~June ~~for the Signing Stockholders who are directors and officers of IDM~~24, ~~not to withdraw the Shares tendered by them in the Offer prior to the termination~~ ~~of the Stockholders’ Agreement~~2009, ~~(iii) for Palo Alto Investors, LLC and its affiliates funds, not to withdraw~~ the ~~Shares~~Company ~~tendered~~issued ~~by them in the Offer prior~~ to the ~~earliest~~Merger ofSub ~~(1) the time Purchaser accepts Shares for payment in the Offer~~13, ~~(2) July 22~~000,000 ~~2009,~~new ~~(3) the~~shares ~~occurrence~~ of a Company ~~Adverse~~ ~~Recommendation~~common ~~Change~~stock (~~as defined in~~ the ~~Merger~~“Top-Up ~~Agreement~~Shares”), ~~(4) the~~for ~~receipt or announcement of~~ an ~~unsolicited~~ ~~offer~~aggregate topurchase ~~acquire IDM from a third party at a higher~~ price ~~than the Offer Price that is reasonably capable~~ of ~~being completed or (5) the termination of the Stockholders’ Agreement, (iv)~~ ~~for Medarex~~$34, ~~Inc.~~320,000, ~~not~~paid tofor ~~withdraw the Shares tendered~~ by ~~them~~delivery ~~in the Offer prior to the earliest~~ of ~~(1) the~~a ~~time~~promissory ~~Purchaser~~note. The ~~accepts~~Top-Up Shares ~~for~~were ~~payment~~issued inwithout registration under the ~~Offer,~~Securities ~~(2) July 22,~~Act ~~2009, (3) the occurrence~~ of a1933, ~~Company Adverse Recommendation Change (~~as ~~defined~~amended in (the ~~Merger~~“Securities ~~Agreement or (4~~Act”), ~~the~~in ~~termination~~reliance ~~of the Stockholders’ Agreement. The Stockholders’ Agreement will terminate~~ upon ~~the~~ ~~earliest of (i)~~ the ~~termination~~exemption offrom ~~the~~registration ~~Merger~~set ~~Agreement~~forth in ~~accordance with its terms,~~ Section 4(ii2) ~~any amendment, waiver or modification to the Merger Agreement made without the IDM stockholders’ prior written approval that changes the form~~ of ~~the Offer Consideration (as defined in the Merger~~ ~~Agreement), decreases~~ the ~~amount~~Securities ~~of the Offer Consideration~~Act, ~~extends~~since ~~the~~this ~~outside~~transaction ~~date~~does ~~for acceptance~~not ofinvolve ~~Shares~~a inpublic ~~the Offer, adds additional conditions to the Offer or otherwise materially and adversely affects IDM’s stockholders and (iii) the time Purchaser accepts Shares for payment in the Offer~~offering.

~~The~~Item ~~form of the Stockholders’ Agreement is filed as Exhibit 99~~5.~~1 to this report and is incorporated by reference herein~~01. ~~The~~Changes ~~description of the Stockholders’ Agreement set forth above does not purport to be complete and is qualified~~ in ~~its~~Control ~~entirety~~of ~~by reference to the Stockholders’ Agreement~~Registrant.

~~Item 5.02.~~The information ~~Departure~~disclosed ofin ~~Directors~~Item or3.01 ~~Certain~~and ~~Officers;~~Item ~~Election~~5.02 ofis ~~Directors;~~hereby ~~Appointment~~incorporated ofby ~~Certain Officers; Compensatory Arrangements of Certain Officers~~reference.

~~Table~~As a result of ~~Contents~~the Merger Sub’s acceptance for purchase on June 23, 2009 of all shares of the Company common stock that had been validly tendered pursuant to the Offer and not properly withdrawn, representing approximately 86.4% of the outstanding shares of the Company, there was a change in control of the Company, and the Parent, as the direct parent of the Merger Sub, controlled the Company. As of the effective time of the Merger on June 24, 2009, the Company became a wholly owned subsidiary of the Parent.

OnThe ~~May 17,~~Merger Sub ~~2009~~acquired the remaining outstanding shares of the Company by means of a merger of the Merger Sub with and into the Company, as a result of which the Company ~~IDM~~became ~~Board~~a wholly owned subsidiary of ~~Directors~~the Parent. At the effective time of the Merger, each share then outstanding (other than shares held in the treasury ~~“Board”~~of the Company and shares that are held by (i) the Parent, inthe Merger ~~connection~~Sub ~~with~~or ~~its~~any ~~approval~~other wholly-owned subsidiary of the Parent or the Company or ~~Merger~~(ii) shareholders ~~Agreement~~who properly demand and perfect appraisal rights under Delaware law) has been converted into the right to receive $2.64 per share, ~~approved~~net to the ~~following~~seller ~~matters:~~in cash, upon the terms and subject to the conditions set forth in the Offer.

~~Vesting~~The ~~Acceleration~~total consideration to be paid for the shares of ~~Options,~~the ~~Restricted~~Company ~~Stock~~common ~~Awards~~stock in the Offer and ~~RSUs~~the Merger, excluding fees and expenses, consists of approximately $67,416,621. The Parent, through its working capital, funded the closing cash consideration for the shares of the Company acquired in the Offer and the Merger.

Assuming the satisfaction of the Minimum Condition and Purchaser’s acceptance and payment for Shares in the Offer (the “Acceptance Time”), the Board approved the full acceleration of vesting for all outstanding options to purchase Shares (the “Options”) under IDM’s 1989 Stock Plan, as amended, and IDM’s 2000 Stock Plan, as amended (the “Option Plans”), contingent and effective immediately prior to the Acceptance Time. In addition, the Board approved an amendment to provide that each Option with an exercise price below the Offer Price shall be amended to provide for a “net exercise” or “cashless exercise” provision so that IDM will reduce the number of Shares issuable upon exercise of each such Option by the number of Shares equal to the original exercise price of such Options multiplied by the number of Shares underlying such Option. The foregoing acceleration of vesting and amendment will apply to Options held by certain of our executive officers and directors. 3

InItem ~~addition,~~5.02. ~~the~~Departure ~~Board approved and confirmed the acceleration~~ of ~~the~~Directors ~~vesting~~or ofCertain ~~each~~Officers; ~~restricted stock~~Election ~~award and each deferred issuance restricted stock unit award (the “RSUs”)~~ of ~~IDM~~Directors; ~~under~~Appointment ~~the Option Plans effective and contingent upon the closing~~ of ~~the~~Certain ~~Merger.~~Officers; ~~Upon~~Compensatory ~~the~~Arrangements ~~closing~~ of ~~the Merger,~~Certain ~~each Share subject to the RSUs shall be cancelled in exchange for the Offer Price~~Officers. The foregoing acceleration of vesting will apply to restricted stock awards and RSUs held by certain of our executive officers and directors and the potential payments related to such acceleration will be included in the Solicitation/Recommendation Statement on Schedule 14D-9 that IDM expects to file with respect to the Offer.

~~Amendment~~Effective as of the effective time of the Merger on June 24, 2009, ~~Transaction~~each ~~Bonus~~of ~~Plan~~Timothy P. Walbert, Michael G. Grey, Robert Beck, M.D., John P. McKearn, Ph.D., and Gregory J. Tibbitts resigned from the Board of Directors of the Company.

~~The~~In ~~Board adopted IDM’s 2009 Transaction Bonus Plan on December 11~~addition, after ~~2008 (as amended,~~ the ~~“Transaction~~ ~~Bonus~~effective ~~Plan”),~~time ~~which~~of ~~provides for bonus payments to IDM’s executive officers in~~ the ~~event~~ ofMerger ~~certain~~on ~~corporate transactions. On May~~June 1724, 2009, ~~the Board approved certain amendments to~~Iwaaki ~~the~~Taniguchi ~~Transaction~~was ~~Bonus~~elected ~~Plan to clarify that transactions such as~~ the ~~Merger~~sole ~~shall~~director ~~be included in the definition~~ of ~~“Change of Control” (as defined in~~ the ~~Transaction~~Company. The ~~Bonus~~following ~~Plan) and that the bonus~~sets ~~payments~~forth ~~under~~biographical ~~the~~information ~~Transaction Bonus Plan will be payable upon the closing~~ of ~~any Change of Control on or prior to August 31, 2009. These bonus payments would be in addition to any payment to which~~ the ~~specified~~new ~~participants under the Transaction Bonus Plan are entitled under any other agreements with IDM.~~ director:

AIwaaki ~~summary~~Taniguchi. Director and President of ~~the~~Takeda ~~Transaction~~America ~~Bonus~~Holdings, Inc. ~~Plan~~since November 2004. Mr. Taniguchi also served Shinsei Bank Limited (399 Park Avenue, asNew ~~amended~~York, isNY ~~filed~~10022, USA) as ~~Exhibit 10.1~~Deputy toChief Representative, ~~this~~New ~~report~~York ~~and~~Representative isOffice (April 2001—December 2003). ~~incorporated~~Mr. Taniguchi bythen ~~reference~~served ~~herein.~~TPC ~~The~~as ~~description~~Manager, ofFinance ~~the~~and ~~Transaction~~Accounting Department ~~Bonus~~(Financing) ~~Plan~~(December 2003 ~~set~~November 2004) ~~forth~~and ~~above~~Senior ~~does~~Manager, ~~not~~Finance ~~purport~~and toAccounting beDepartment ~~complete~~(Financing) (November 2004 September 2006). Mr. Taniguchi’s business address and telephone number is ~~qualified~~c/o inTakeda America ~~its~~Holdings, Inc., ~~entirety~~767 byThird ~~reference~~Avenue, to8th ~~the~~Floor, ~~Transaction~~New York, NY 10017, ~~Bonus~~USA, ~~Plan~~212-421-6950.

~~Termination~~On June 24, 2009, effective as of ~~Directors’~~the ~~Deferred~~effective ~~Compensation~~time ~~Plan~~of the Merger, the following officers of the Company were terminated: Timothy P. Walbert, Robert J. De Vaere, Jeffrey W. Sherman, M.D. and Timothy C. Melkus.

~~The~~In ~~Board also approved the termination of IDM’s Amended and Restated Directors’ Deferred~~addition, ~~Compensation~~after ~~Plan (~~the ~~“Directors’ Deferred Compensation Plan”), contingent and~~ effective ~~upon~~time ~~the closing~~ of the Merger, ~~and~~on ~~the~~June 24, ~~payment~~2009, ofIwaaki ~~all benefits under the Directors’ Deferred Compensation~~Taniguchi ~~Plan~~was toelected the ~~participant directors in that plan in a single lump sum in accordance with applicable requirements related to Section 409A of the Internal Revenue Code of 1986~~President, asTreasurer ~~amended. Mike Grey~~ and ~~John~~Secretary ~~McKearn, who are directors~~ of ~~IDM, will be entitled to receive approximately $126,826 and $18,242, respectively, in connection with~~ the ~~acceleration~~Company. See ofbiographical ~~payment~~information ~~of such directors’ Directors’ Deferred Compensation Plan accounts~~above.

Item 9 5.0103. ~~Financial~~Amendments ~~Statements~~to ~~and~~Articles ~~Exhibits~~of Incorporation or Bylaws; Change of Fiscal Year.

~~(d)~~Pursuant ~~Exhibits~~to the Merger Agreement, at the effective time of the Merger, the certificate of incorporation of the Company was amended and restated in its entirety, a copy of which is filed as Exhibit 3.1 to this Form 8-K and incorporated herein by reference. Also, following the consummation of the Merger, the Bylaws of the Company were amended and restated in their entirety, a copy of which is filed as Exhibit 3.2 to this Form 8-K and incorporated herein by reference.

~~Table~~Item of9.01. ~~Contents~~Financial Statements and Exhibits.

2.1		Agreement and Plan of Merger, dated May 18, 2009, by and among Takeda America Holdings, Inc., Jade Subsidiary Corporation and IDM Pharma, Inc.
Exhibit 3.1	Amended and Restated Certificate of Incorporation of the Company.
10.1		2009 Transaction Bonus Plan, as amended on May 17, 2009.
Exhibit 3.2	Amended and Restated Bylaws of the Company.
99.1		Stockholders’ Agreement, dated May 18, 2009, by and among Takeda America Holdings, Inc. and certain stockholders of IDM Pharma, Inc.
Exhibit 99.1	Press release issued by Takeda Pharmaceutical Company Limited on June 23, 2009 announcing the completion of the Offer.
99.2		Joint press release of Takeda Pharmaceutical Company Limited and IDM Pharma, Inc. dated May 18, 2009 (incorporated herein by reference to the Joint Press Release filed under the cover of Schedule 14D- 9C by IDM Pharma, Inc. on May 18, 2009).
Exhibit 99.2	Press release issued by Takeda Pharmaceutical Company Limited on June 24, 2009 announcing the completion of the acquisition.

~~Table of Contents~~4

~~Additional Information and Where To Find It~~ SIGNATURE

~~This~~Pursuant ~~report is neither an offer~~ to ~~purchase nor a solicitation of an offer to sell Shares of IDM. The tender offer for~~ the ~~Shares of IDM has not commenced. Stockholders of IDM are urged to read the~~requirements relevant tender offer documents when they become available because they will contain important information that stockholders should consider before making any decision regarding tendering their Shares. At the time the Offer is commenced, Takeda America and Purchaser will file a Tender Offer Statement on Schedule TO and related tender offer materials with the SEC, and IDM will file a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the Offer. The tender offer materials (including an Offer to Purchase, a related Letter of ~~Transmittal and certain other offer documents) and~~ the ~~Solicitation/Recommendation~~Securities ~~Statement~~Exchange ~~will~~Act ~~contain important information, which should be read carefully before any decision is made with respect to the tender offer. The Offer to Purchase, the related Letter~~ of ~~Transmittal and certain other offer documents~~1934, ~~as well as~~ the ~~Solicitation/Recommendation~~ ~~Statement,~~Registrant ~~will~~has beduly ~~made~~caused ~~available to all stockholders of IDM at no~~this ~~expense~~report to ~~them.~~be ~~The~~signed ~~tender~~on ~~offer~~its ~~materials~~behalf ~~and~~by the ~~Solicitation/Recommendation~~undersigned ~~Statement~~hereunto ~~will~~duly ~~be made available for free at the SEC’s website at http://www~~authorized.~~sec.gov. In addition, stockholders will be able to obtain a free copy of these documents (when they become available) at www.idm-pharma.com.~~

Safe Harbor for Forward-Looking Statements

	IDM Pharma, Inc.

Date: June 26, 2009	By:	/s/ Laurie B. Keating
		Name: Laurie B. Keating
		Title: Attorney-in-fact

This report includes forward-looking statements that are subject to risks, uncertainties and other factors, including the risks that the acquisition of IDM will not be consummated as the transactions are subject to certain closing conditions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including statements regarding the anticipated timing of completion of the transactions; the ability to complete the transactions considering the various closing conditions; any statements of expectation or belief; and any statements of assumptions underlying any of the foregoing. These and other risks affecting IDM and its drug development programs, intellectual property rights, personnel and business are more fully discussed in IDM’s annual report on Form 10-K, quarterly reports on Form 10-Q and other filings made with the SEC. IDM expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. 5

~~Table of Contents~~EXHIBIT INDEX

SIGNATURES

Exhibit 3.1	Amended and Restated Certificate of Incorporation of the Company.

Exhibit 3.2	Amended and Restated Bylaws of the Company.

Exhibit 99.1	Press release issued by Takeda Pharmaceutical Company Limited on June 23, 2009 announcing the completion of the Offer.

Exhibit 99.2	Press release issued by the Takeda Pharmaceutical Company Limited on June 24, 2009 announcing the completion of the acquisition.

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~ 6

	IDM PHARMA, INC.
Date: May 18, 2009	By:	/s/ Robert J. De Vaere
		Robert J. De Vaere
		Senior Vice President, Finance and Administration and Chief Financial Officer

Schedule 1

~~Table~~POWER ofOF ~~Contents~~ATTORNEY

~~INDEX~~KNOW TOALL ~~EXHIBITS~~PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Laurie Bartlett Keating and Jeannette Potts, and each of them, its true and lawful attorneys-in-fact and agents with full power of substitution and resubstitution, for it and in its name, place, and stead, in any and all capacities, to sign any and all filings, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission relating to the tender offer for shares of common stock of IDM Pharma, Inc. or subsequent merger of Jade Subsidiary Corporation with IDM Pharma, Inc., and hereby grants to each such attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.

Exhibit No.		Description
2.1		Agreement and Plan of Merger, dated May 18, 2009, by and among Takeda America Holdings, Inc., Jade Subsidiary Corporation and IDM Pharma, Inc.
10.1		2009 Transaction Bonus Plan, as amended on May 17, 2009.
99.1		Stockholders’ Agreement, dated May 18, 2009, by and among Takeda America Holdings, Inc. and certain stockholders of IDM Pharma, Inc.
99.2		Joint press release of Takeda Pharmaceutical Company Limited and IDM Pharma, Inc. dated May 18, 2009 (incorporated herein by reference to the Joint Press Release filed under the cover of Schedule 14D- 9C by IDM Pharma, Inc. on May 18, 2009).

Dated: May 28, 2009

	TAKEDA AMERICA HOLDINGS, INC.

	By:	/s/ Iwaaki Taniguchi
	Name:	Iwaaki Taniguchi
	Title:	President

	TAKEDA PHARMACEUTICAL COMPANY LIMITED

	By:	/s/ Hiroshi Shinha
	Name:	Hiroshi Shinha
	Title:	Member of the Board
		General Manager, Legal Department

Filing Compare · IDM PHARMA, INC.